Detalhe da pesquisa
1.
Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages.
Cell
; 184(11): 2988-3005.e16, 2021 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34019793
2.
The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8+ T Cell Fitness and Functionality.
Immunity
; 51(3): 491-507.e7, 2019 09 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31533057
3.
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Oncologist
; 29(3): 254-262, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38262444
4.
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma.
Invest New Drugs
; 42(2): 179-184, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38372949
5.
The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8+ T Cell Fitness and Functionality.
Immunity
; 52(1): 201-202, 2020 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31940270
6.
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
J Natl Compr Canc Netw
; 22(1): 4-16, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394781
7.
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.
Oncologist
; 28(4): 333-340, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36576173
8.
Leptin Augments Antitumor Immunity in Obesity by Repolarizing Tumor-Associated Macrophages.
J Immunol
; 207(12): 3122-3130, 2021 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34772698
9.
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(1): 71-90, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34991070
10.
The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma.
Oncologist
; 25(3): e602-e605, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32162820
11.
Sequencing checkpoint inhibitor therapy in renal cell carcinoma.
Lancet
; 402(10397): 160-161, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37290460
12.
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
Lancet Oncol
; 19(3): 310-322, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29449192
13.
Immune Checkpoint Inhibitor Therapy in Patients With Autoimmune Disease.
Oncology (Williston Park)
; 32(4): 190-4, 2018 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29684232
14.
A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma.
Clin Cancer Res
; : OF1-OF10, 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38652038
15.
Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.
Clin Cancer Res
; 30(9): 1750-1757, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38393723
16.
A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors.
JTO Clin Res Rep
; 5(2): 100619, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38328473
17.
Metabolite profiling of human renal cell carcinoma reveals tissue-origin dominance in nutrient availability.
bioRxiv
; 2024 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38187626
18.
Metabolite profiling of human renal cell carcinoma reveals tissue-origin dominance in nutrient availability.
Elife
; 132024 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38787918
19.
VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis.
J Clin Invest
; 134(8)2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38618956
20.
Triplet Strategies in Metastatic Clear Cell Renal Cell Carcinoma: A Worthy Option in the First-Line Setting?
Am Soc Clin Oncol Educ Book
; 43: e389650, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37207297